8-K: Royalty Pharma Increases Stake in Evrysdi Royalties with $242 Million Deal

Royalty Pharma has increased its ownership of royalties from the drug Evrysdi by acquiring a portion of PTC Therapeutics' retained royalties for $242 million upfront.

Summary

• Royalty Pharma has acquired half of PTC Therapeutics' remaining royalties on the drug Evrysdi for approximately $242 million upfront.
• This transaction increases Royalty Pharma's total ownership of Evrysdi royalties from 81% to 90.5% before a cap, translating to a royalty rate of 7.2% to 14.5% on worldwide net sales.
• The deal stems from an option granted to PTC in a previous agreement from October 2023.
• Evrysdi, marketed by Roche, generated approximately $1.6 billion in sales in 2023, a 39% increase at constant exchange rates compared to the previous year.
• PTC retains an option to sell its remaining 9.5% of the Evrysdi royalty to Royalty Pharma for $250 million less royalties received until December 31, 2025.
• Royalty Pharma will begin receiving the increased royalty payments starting with royalties paid for the second quarter of 2024 sales.

Sentiment

Score: 7

Explanation: The document reflects a positive development for Royalty Pharma, increasing its stake in a growing drug. However, there are risks associated with future sales and potential additional payments.

Positives

• Royalty Pharma has increased its stake in a successful drug, Evrysdi, which saw a 39% sales increase in 2023.
• The transaction provides immediate increased royalty revenue for Royalty Pharma starting in the second quarter of 2024.
• The option for Royalty Pharma to acquire the remaining royalties from PTC provides a potential future growth opportunity.
• The deal is expected to increase Royalty Pharma's royalty rate to between 7.2% and 14.5%.

Negatives

• The transaction requires a significant upfront payment of $242 million.
• There is a potential future outlay of $250 million less royalties received if PTC exercises its option to sell the remaining royalties.
• The royalty payments are subject to a cap of $1.3 billion from the initial 2020 transaction, after which Royalty Pharma's share decreases to 84%.

Risks

• The future sales of Evrysdi may not continue to grow at the same rate.
• The $1.3 billion cap on royalties from the initial 2020 transaction will reduce Royalty Pharma's share of royalties after that threshold is reached.
• PTC may exercise its option to sell the remaining royalties, requiring an additional $250 million less royalties received from Royalty Pharma.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The document includes forward-looking statements regarding the company's expectations, but cautions that these are subject to risks and uncertainties and should not be unduly relied upon. The company does not commit to updating these statements.

Industry Context

This transaction highlights the ongoing trend of pharmaceutical companies monetizing their royalty streams to fund further research and development or other strategic initiatives. Royalty Pharma's strategy of acquiring royalties on successful drugs is a common practice in the biopharmaceutical industry.

Comparison to Industry Standards

• Royalty Pharma's acquisition of Evrysdi royalties is similar to other deals in the pharmaceutical royalty space, where companies acquire rights to future revenue streams from successful drugs.
• Comparable companies like Healthcare Royalty Partners and DRI Capital also engage in similar royalty acquisition strategies.
• The 39% year-over-year growth of Evrysdi sales is a strong indicator of the drug's market performance, which is a key factor in the value of the royalty stream.
• The tiered royalty structure is a common practice in the industry, where royalty rates increase with sales volume.

Stakeholder Impact

• Shareholders of Royalty Pharma will benefit from the increased royalty revenue.
• PTC Therapeutics will receive a significant upfront payment, which can be used for further development.
• Patients using Evrysdi will continue to have access to the drug.

Next Steps

• Royalty Pharma will begin receiving increased royalty payments from the second quarter of 2024.
• PTC may exercise its option to sell its remaining royalties to Royalty Pharma before December 31, 2025.

Key Dates

Keywords

Royalty Pharma, PTC Therapeutics, Evrysdi, Royalties, Spinal Muscular Atrophy, SMA, Pharmaceuticals, Drug Sales, Acquisition